Login to Your Account

Other News To Note

Thursday, January 27, 2011
Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said preclinical data using its next-generation intradermal electroporation delivery devices showed DNA delivery yielded levels of immunogenicity in terms of both antibody and T-cell responses and/or efficacy against a virus challenge that is comparable to intramuscular electroporation devices currently in testing.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription